Angiography

Worldwide CT Scanners Industry to 2026 - Expanded Applications of the 16-slice CT are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022
Medical Devices, Health, Radiology, Cardiology, Oncology, Growth, Lists of diseases, Global, Conditional sentence, Cancer, Angiography, Brain, Fossil, Elective surgery, Vaccination, Population, CAGR, Kidney, Physics, Cardiology, Degenerative disease, Medical imaging

The Global CT Scanners Market is segmented by slice, modality, device architecture, application, end-users, and regional distribution.

Key Points: 
  • The Global CT Scanners Market is segmented by slice, modality, device architecture, application, end-users, and regional distribution.
  • To analyze the historical growth of the market size of the Global CT Scanners Market from 2016 to 2020.
  • To estimate and forecast the market size of the Global CT Scanners Market from 2021 to 2026 and growth rate until 2026.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global CT Scanners Market.

Four-party consortium conducts a demonstration experiment of emergency medical care using 5G at St. Marianna University School of Medicine Hospital

Retrieved on: 
Wednesday, January 19, 2022
Patient, Technology, Smartglasses, Nursing, Google Images, Glass, Tablet, Angiography, Experiment, Travel, Triage, CT, Diagnosis, Emergency, Trauma, AI, Infection, Hospital, National Association Medical Staff Services, Coronavirus, Television, Health insurance, Medicine, Medical imaging, ICU

In addition, this enables more doctors and medical staff to share information about the situation at the medical sites.

Key Points: 
  • In addition, this enables more doctors and medical staff to share information about the situation at the medical sites.
  • In the experiment, videos of an emergency patient on transfer on a stretcher inside the hospital will be livestreamed to remote doctors' tablets using 5G.
  • The experiment will verify the feasibility of wireless mass video data transmission using unique features of 5G technology that is otherwise difficult.
  • 5G enables the transmission of high-definition video data, which in turn secures the level of resolution required for AI-based analysis.

Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Retrieved on: 
Wednesday, December 15, 2021
Therapy, Retina, AMD, BLA, FDA, Symposia, Nasdaq, Professor, Engineer, OCT, Continuing medical education, Patient, BRVO, Department, Angiography, FEBO, International Congress on Tuberculosis, CPD, MD, Bevacizumab, Industry, GLOBE, University, Part, DME, PHSA, CME, Pharmaceutical industry, Ophthalmology

The presentation will take place at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia, on Saturday, December 18, 2021.

Key Points: 
  • The presentation will take place at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia, on Saturday, December 18, 2021.
  • The results observed for ONS-5010 in the NORSE TWO trial are potentially of great significance for retinal specialists and their patients suffering from wet AMD, said Dr. Bandello.
  • The International Congress on OCT and OCT Angiography in Rome (ICOOR) and the FLORetina Symposia are conducted under the auspices of AP Meetings.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve

Retrieved on: 
Thursday, December 9, 2021
PMI, Myocardial infarction, Angiography, Research, Adenosine, Medical imaging, CAAS, FFR, Patient, Method, Carotid artery stenosis, Erasmus MC, Roemheld syndrome, FAST, ECRI, Pharmaceutical industry

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.

Key Points: 
  • vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.
  • CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) and adenosine.
  • The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
  • PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector.

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve

Retrieved on: 
Thursday, December 9, 2021
PMI, Myocardial infarction, Angiography, Research, Adenosine, Medical imaging, CAAS, FFR, Patient, Method, Carotid artery stenosis, Erasmus MC, Roemheld syndrome, FAST, ECRI, Pharmaceutical industry

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.

Key Points: 
  • vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.
  • CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) and adenosine.
  • The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
  • PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector.

RSIP Vision Presents New Technology for Non-Invasive Planning of Coronary Intervention

Retrieved on: 
Wednesday, December 8, 2021
Health, Medical Devices, Technology, Surgery, Other Technology, Software, Cardiology, Medical device, QCA, CA, Angiography, Coronary artery disease, Technology, DL, Percutaneous coronary intervention, FFR, Google Images, SYNTAX, Moyamoya disease, CEO, PCI, Industry, Software, Coronary artery bypass surgery, Multimedia, Stenosis, CABG, RSIP, Survival, Diagnosis, 3D, Algorithm, Medical imaging

RSIP Vision , an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new coronary artery modelling technology.

Key Points: 
  • RSIP Vision , an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new coronary artery modelling technology.
  • This technology enables quick and accurate reconstruction of the coronary vasculature during angiography into a 3D model.
  • This technology will be useful in percutaneous coronary intervention (PCI) planning, reducing the need for additional interventions and decreasing the chance of adverse events due to incorrect stent selection.
  • RSIP Vision is driving innovation in Visual Intelligence for Medical Devices, through advanced AI and computer vision applications.

FDA Clears 12 New XO Cross Microcatheters

Retrieved on: 
Tuesday, November 2, 2021
Cath, Torque, Technology, Agent handling, Angiography, Advanced cardiac life support, FDA, View, CLI, Moyamoya disease, XO, Sheath, Ischemia, PARK, Federal Food, Drug, and Cosmetic Act, Multimedia, PAD, Catheter, Health, CE marking, Medical imaging, Extrusion

PARK CITY, Utah, Nov. 2, 2021 /PRNewswire/ --Transit Scientific announced the FDA clearance of new hydrophilic-coated XO Cross Microcatheters for guidewire support, exchange, and contrast media injection in the peripheral vasculature.

Key Points: 
  • PARK CITY, Utah, Nov. 2, 2021 /PRNewswire/ --Transit Scientific announced the FDA clearance of new hydrophilic-coated XO Cross Microcatheters for guidewire support, exchange, and contrast media injection in the peripheral vasculature.
  • This 510k clearance includes new 2Fr XO Cross 14 Microcatheters, 2.6Fr XO Cross 18 Microcatheters, and 3.8Fr XO Cross 35 Support Catheters for use with standard 0.014", 0.018", and 0.035" guidewires in 90cm, 135cm, 150cm, and 175cm working lengths.
  • Transit Scientific is a commercial stage company that designed, developed, and commercialized the XO Cross and XO Score product platforms.
  • The FDA and CE-Mark cleared XO Cross Microcatheter platform includes 2F 3.8F metal-alloy microcatheters to guide and support guidewire access, allow wire exchanges, and deliver saline or contrast agents in the peripheral vasculature.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA21

Retrieved on: 
Tuesday, October 5, 2021
Well, Mortality, NCDR, Man, CTO, VIVA, De novo, Macroinvertebrate Community Index, Diagnosis, PTA, Patient, Employment, Categorization, Randomized controlled trial, Medicare, Multimedia, LL, Boston Scientific, Atherectomy, Angiography, Wynn Las Vegas, White, Hypertension, Odds ratio, PVI, ISR, Calcification, TLR, Diabetes, Vascular disease, PAD, AOR, Freedom, Prevalence, DCB, Awareness, Ranger, Peripheral vascular examination, Center, Male, CI, Peripheral artery disease, Research, Association, Centers for Medicare & Medicaid Services, Safety, Ahr, Kaplan–Meier estimator, Index, Operational technology, DCI, Blood vessel, CLI, Amputation, Education, Medical imaging, Pharmaceutical industry, Medicine

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • This presentation is the first report on the long-term safety and effectiveness follow-up outcomes of these independent prespecified cohorts.
  • The IN.PACT Global Study was a prospective, multicenter, single-arm study conducted at 64 international sites that enrolled 1,535 participants, including some with complex lesions.
  • Assessments through 5 years included freedom from clinically driven target lesion revascularization (CD-TLR), safety composite, and major adverse events.

Outlook on the Choroidal Neovascularization Global Market to 2026 - by Product Type, Type of Diagnosis, Treatment Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 30, 2021
Health, General Health, Retina, Adoption, OCT, Bruch, Histoplasmosis, Fluorescein angiography, Sterilization, FA, Choroid, Diagnosis, Retinal pigment epithelium, Angioid streaks, Solution, RPE, Distortion, Patient, Choroidal neovascularization, Angiography, PDT, Indocyanine green, Industry, ARMD, ICG, Growth, Prevalence, Disease, Risk, VEGF, COVID-19, Research, CNV, Blood, R, Investment, Coronavirus, Pharmaceutical industry, Potash

Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.

Key Points: 
  • Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.
  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What is the structure of the global choroidal neovascularization market and who are the key players?

Global Angioscope Device Market (2021 to 2026) - by Type, Procedure, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Medical Devices, Health, Cardiovascular diseases, Global health, Non-communicable disease, Cardiovascular disease

One of the major factors anticipated to drive the growth of the global angioscope device market during the forecast period is the research and developments being conducted in angiography and the consequent innovations, which are providing advancements in angioscopy.

Key Points: 
  • One of the major factors anticipated to drive the growth of the global angioscope device market during the forecast period is the research and developments being conducted in angiography and the consequent innovations, which are providing advancements in angioscopy.
  • The growing cases of cardiovascular diseases around the world have led to the increased use of angioscopy, which is anticipated to surge the growth of the global angioscope device market during the forecast period.
  • The increased threat due to CVDs has led to increased demand for angioscope, which is anticipated to propel the growth of the global angioscope device market during the assessment period.
  • The Asia Pacific region is anticipated to witness substantial growth due to rising investment in healthcare and the growing number of CVD cases.